Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,651 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
Yen I, Shanahan F, Lee J, Hong YS, Shin SJ, Moore AR, Sudhamsu J, Chang MT, Bae I, Dela Cruz D, Hunsaker T, Klijn C, Liau NPD, Lin E, Martin SE, Modrusan Z, Piskol R, Segal E, Venkatanarayan A, Ye X, Yin J, Zhang L, Kim JS, Lim HS, Kim KP, Kim YJ, Han HS, Lee SJ, Kim ST, Jung M, Hong YH, Noh YS, Choi M, Han O, Nowicka M, Srinivasan S, Yan Y, Kim TW, Malek S. Yen I, et al. Among authors: lee sj, lee j. Nature. 2021 Jun;594(7863):418-423. doi: 10.1038/s41586-021-03515-1. Epub 2021 May 5. Nature. 2021. PMID: 33953400 Clinical Trial.
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Park YH, Im SA, Kim SB, Sohn JH, Lee KS, Chae YS, Lee KH, Kim JH, Im YH, Kim JY, Kim TY, Lee KH, Ahn JH, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH; Korean Cancer Study Group (KCSG). Park YH, et al. Among authors: lee sj, lee ks, lee kh. Eur J Cancer. 2017 Nov;86:385-393. doi: 10.1016/j.ejca.2017.10.002. Epub 2017 Nov 5. Eur J Cancer. 2017. PMID: 29100193 Clinical Trial.
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11).
Kim JY, Park S, Im SA, Kim SB, Sohn J, Lee KS, Chae YS, Lee KH, Kim JH, Im YH, Kim TY, Lee KH, Ahn JH, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH, Park YH; Korean Cancer Study Group. Kim JY, et al. Among authors: lee sj, lee ks, lee kh. Cancer Commun (Lond). 2019 May 28;39(1):29. doi: 10.1186/s40880-019-0375-7. Cancer Commun (Lond). 2019. PMID: 31138332 Free PMC article. Clinical Trial.
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
Park YH, Kim TY, Im YH, Lee KS, Park IH, Sohn J, Lee SH, Im SA, Kim JH, Kim SH, Lee SJ, Koh SJ, Lee KH, Choi YJ, Cho EK, Lee S, Kang SY, Seo JH, Kim SB, Jung KH. Park YH, et al. Among authors: lee sh, lee sj, lee ks, lee kh, lee s. Cancer Res Treat. 2017 Apr;49(2):423-429. doi: 10.4143/crt.2016.191. Epub 2016 Aug 3. Cancer Res Treat. 2017. PMID: 27488876 Free PMC article. Clinical Trial.
Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea.
Lee JB, Jung M, Kim JH, Kim BH, Kim Y, Kim YS, Kim BC, Kim J, Moon SH, Park KU, Park M, Park HJ, Sim SH, Yoon HM, Lee SJ, Lee E, Chun JY, Chung YK, Jung SY, Chung J, Lee ES, Chung HC, Yun T, Rha SY. Lee JB, et al. Among authors: lee e, lee sj, lee es. Cancer Res Treat. 2021 Apr;53(2):323-329. doi: 10.4143/crt.2020.1256. Epub 2021 Mar 15. Cancer Res Treat. 2021. PMID: 33721486 Free PMC article.
12,651 results
You have reached the last available page of results. Please see the User Guide for more information.